Could a simple drug combo speed up stomach ulcer healing after cancer surgery?

NCT ID NCT07312370

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether adding sucralfate (a protective coating agent) to standard esomeprazole (a stomach acid reducer) helps heal artificial ulcers created during endoscopic surgery for early stomach cancer or precancerous growths. About 120 adults will be randomly assigned to get either the combo or esomeprazole alone for 8 weeks. The main goal is to see how much the ulcer shrinks after 4 weeks, and whether the combo reduces bleeding and other complications.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Esomeprazole and sucralfate suspension

What this could lead to

If successful, this combination could become a standard treatment to help stomach ulcers heal faster and reduce bleeding after endoscopic surgery for early gastric cancer.

What could go wrong

This is a small, early-phase trial with only 120 participants, so results may not apply to everyone. Adding sucralfate may not provide significant benefit over esomeprazole alone.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTRIC NEOPLASMS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

active peptic ulcer disease gastric neoplasm gastric ulcer intraepithelial neoplasia microinvasive gastric cancer peptic ulcer disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The First Hospital of Lanzhou University

    Lanzhou, Gansu, 730000, China

    Contact Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••